This is consistent with the data derived from targeted deletion of Pdgfrβ, and these results further confirm that inhibition of Pdgfrβ-Pkcα signaling promotes Brca1-deficient tumor cell death and MET. This evidence concerns the gene PDGFRB and neoplasm.